Experience with Direct Acting Agents for the Treatment of Hepatitis C in Flanders.
Introduction: Hepatitis C (HCV) remains one of the main causes of chronic liver disease worldwide. The impact of chronic HCV on the long-term ranges widely, from minimal histologic changes to decompensated cirrhosis or hepatocellular carcinoma. These last years, the development of direct acting antivirals have revolutionized HCV care. We present the experience in the KU Leuven affiliated hospitals with the latest generation of direct acting antivirals. These are therapies without concomitant use of interferon, such as simeprevir, sofosbuvir, daclatasvir, and ombitasvir/paritaprevir ritonavir –... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | conferenceObject |
Erscheinungsdatum: | 2016 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26697757 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/1942/23090 |